Biological functions of the m6A reader YTHDF2 and its role in central nervous system disorders

IF 5.3 2区医学 Q1 PHARMACOLOGY & PHARMACY

Biochemical pharmacology Pub Date : 2024-10-16 DOI:10.1016/j.bcp.2024.116576

Lili Song , Huimin Liu , Weiyu Yang , Hongqing Yin , Jiayi Wang , Maojuan Guo , Zhen Yang

引用次数: 0

Abstract

N6-methyladenosine (m6A) is a prevalent mRNA modification in eukaryotic cells, characterized by its reversible nature. YTH structural domain family protein 2 (YTHDF2), a key reader of m6A, plays a crucial role in identifying and binding m6A-containing RNAs, thereby influencing RNA metabolism through various functional mechanisms. The upstream and downstream targets of YTHDF2 are critical in the pathogenesis of various central nervous system (CNS) diseases, affecting disease development by regulating signaling pathways and gene expression. This paper provides an overview of current research on the role of YTHDF2 in CNS diseases and investigates the regulatory mechanisms by which YTHDF2 influences the development of these conditions. This exploration aims to improve understanding of disease pathogenesis and offer novel insights for the targeted prevention and treatment of neurological disorders.

Abstract Image

查看原文本刊更多论文

m6A 阅读器 YTHDF2 的生物功能及其在中枢神经系统疾病中的作用。

N6-甲基腺苷（m6A）是真核细胞中普遍存在的一种mRNA修饰，具有可逆性。YTH 结构域家族蛋白 2（YTHDF2）是 m6A 的关键阅读器，在识别和结合含 m6A 的 RNA 方面发挥着关键作用，从而通过各种功能机制影响 RNA 代谢。YTHDF2 的上游和下游靶标在各种中枢神经系统（CNS）疾病的发病机制中至关重要，它们通过调节信号通路和基因表达影响疾病的发展。本文概述了目前有关 YTHDF2 在中枢神经系统疾病中作用的研究，并探讨了 YTHDF2 影响这些疾病发展的调控机制。这一探索旨在提高人们对疾病发病机制的认识，并为有针对性地预防和治疗神经系统疾病提供新的见解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biochemical pharmacology 医学-药学

CiteScore

10.30

自引率

1.70%

发文量

420

审稿时长

17 days

期刊介绍： Biochemical Pharmacology publishes original research findings, Commentaries and review articles related to the elucidation of cellular and tissue function(s) at the biochemical and molecular levels, the modification of cellular phenotype(s) by genetic, transcriptional/translational or drug/compound-induced modifications, as well as the pharmacodynamics and pharmacokinetics of xenobiotics and drugs, the latter including both small molecules and biologics. The journal''s target audience includes scientists engaged in the identification and study of the mechanisms of action of xenobiotics, biologics and drugs and in the drug discovery and development process. All areas of cellular biology and cellular, tissue/organ and whole animal pharmacology fall within the scope of the journal. Drug classes covered include anti-infectives, anti-inflammatory agents, chemotherapeutics, cardiovascular, endocrinological, immunological, metabolic, neurological and psychiatric drugs, as well as research on drug metabolism and kinetics. While medicinal chemistry is a topic of complimentary interest, manuscripts in this area must contain sufficient biological data to characterize pharmacologically the compounds reported. Submissions describing work focused predominately on chemical synthesis and molecular modeling will not be considered for review. While particular emphasis is placed on reporting the results of molecular and biochemical studies, research involving the use of tissue and animal models of human pathophysiology and toxicology is of interest to the extent that it helps define drug mechanisms of action, safety and efficacy.